By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

AMAG Pharmaceuticals, Inc. 

1100 Winter Street

Waltham  Massachusetts  02451  U.S.A.
Phone: 617-498–3300 Fax: 617-499-3361


SEARCH JOBS

Founded in 1981, AMAG Pharmaceuticals is committed to improving the health outcomes of patients through the development and commercialization of specialty pharmaceutical products.

AMAG currently markets a therapeutic intravenous iron compound for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) and an oral rinse for the management of oral mucositis in the United States. To learn more about our products, click here. Along with driving organic growth of its lead product, AMAG intends to expand its portfolio with additional commercial-stage specialty pharmaceuticals. The company is seeking complementary products that leverage the company's commercial footprint and focus on hematology and oncology centers and hospital infusion centers.
Our iron oxide particles are composed of bioavailable iron that is easily absorbed by the body and incorporated into the body's iron stores. As a result, products using our core technology are well suited for use in intravenous iron replacement therapy.


Key Statistics


Email: contactus@amagpharma.com
Ownership: Public

Web Site: AMAG
Employees: 51-200
Symbol: AMAG
 




Segment
Pharmaceuticals





Company News
AMAG (AMAG) Reports Second Quarter 2016 Financial Results And Provides Corporate Update 8/9/2016 10:47:55 AM
AMAG (AMAG) To Host Conference Call On August 9, 2016 At 8:00 A.M. ET To Discuss Financial Results For The Second Quarter Ended June 30, 2016 7/21/2016 7:36:04 AM
AMAG (AMAG) CEO William Heide Elected To PhRMA Board Of Directors 7/18/2016 8:13:21 AM
AMAG (AMAG) Appoints Mark Stanton As Vice President, Market Access & Corporate Accounts 7/12/2016 8:00:15 AM
10 Massachusetts Biotechs that Grew Their Headcount by at Least 40% in 2015 3/23/2016 6:40:48 AM
AMAG (AMAG) Announces First Patient Enrolled In Head-To-Head Phase III Clinical Trial Evaluating Feraheme® In Adults With Iron Deficiency Anemia 3/16/2016 8:17:01 AM
AMAG (AMAG) Responds To Recent Complete Response Letter From The FDA For The Single-Dose, Preservative-Free Vial Of Makena 11/23/2015 7:22:25 AM
FDA Rejects AMAG (AMAG)'s Single-Dose Makena Again 11/19/2015 6:37:33 AM
AMAG (AMAG) Reports Third Quarter 2015 Financial Results 11/3/2015 9:02:51 AM
AMAG (AMAG) Announces Head-To-Head Phase III Clinical Trial Evaluating Feraheme In Adults With Iron Deficiency Anemia 10/28/2015 7:07:39 AM
12345678910...
//-->